EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
- BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
The issuer is solely responsible for the content of this announcement. - The rise in bond yields weighed heavily on biotech stocks as well as the stock market in general.
- BB Biotech benefited from the dollar's appreciation, but it was also exposed to the sustained selling pressure on equity markets.
- BB Biotech traded within a narrow range during the third quarter, closing slightly higher at CHF 41.35 per share.